Generic Ozempic: none in the US until December 2031, where generics already sell, and what to buy instead

There is no generic Ozempic in the United States, and there will not be one before 5 December 2031. That is the date the FDA Orange Book gives for patent 8,129,343, the semaglutide compound patent listed for Ozempic, Wegovy and Rybelsus alike.¹²³ Generic semaglutide does exist: it went on sale in India on 21 March 2026 and in Canada in May.¹³ A US buyer cannot legally bring it home. What you can buy today is compounded semaglutide from $69 a month on our board, or brand Wegovy, which Novo Nordisk sells direct at $349 a month for the pen and from $149 for the pill.²⁰

The answer in one table

What "generic" means, and what it does not

Three different products get called "generic Ozempic" online. Only one of them is a generic.

• A generic drug is a copy that FDA approves through an abbreviated application (an ANDA). FDA's rule: it "is required to be the same as a brand-name medicine in dosage, safety, effectiveness, strength, stability, and quality, as well as in the way it is taken."⁴ It can be approved once the brand's patents and exclusivities expire, "or if the patents are successfully challenged by the generic drug company."⁴ None is approved for semaglutide in the US.
• Compounded semaglutide is mixed by a licensed pharmacy for one patient's prescription. It has the same active ingredient, but nobody at FDA reviews the finished product: unapproved versions "do not undergo FDA's review for safety, effectiveness and quality before they are marketed."¹⁹ It is legal under conditions FDA spells out, and it is what most US sellers mean when they say "generic semaglutide".
• Brand self-pay is Novo Nordisk's own Ozempic or Wegovy, sold for cash below list price through NovoCare. It is the approved product at a lower price, not a generic.

"Semaglutide" itself is the generic name: the non-brand name of the molecule in Ozempic, Wegovy and Rybelsus. Having a generic name does not mean a generic drug is on the shelf.

One GLP-1 does have a US generic. On 23 December 2024 FDA "approved the first generic referencing Victoza (liraglutide injection)", a month after "a generic referencing Byetta (exenatide)".²² Both are older GLP-1 drugs. Neither is semaglutide.

The US patent wall, read from the Orange Book today

The Orange Book is FDA's register of the patents a brand says cover its drug. We read the semaglutide listings on 8 October 2026. The two that matter most are the compound patents, which claim the molecule itself:

Sources: Orange Book listings for Ozempic, Wegovy and Rybelsus.¹²³

So the March 2026 expiry changed nothing for a US pharmacy shelf. A second compound patent on the same drug substance runs another five years and eight months. Behind it, Wegovy's formulation patents run to 2041, and a generic maker has to design around them or overturn them too. FDA itself warns readers not to treat the list as the last word: "Orange Book users should not rely on an Orange Book patent listing ... to determine the range of patent claims that may be asserted".¹

Exclusivities: shorter, and narrower

FDA also grants brands periods of marketing exclusivity, separate from patents. For semaglutide they are tied to newer uses, and each protects that use, not the molecule. The Orange Book lists Wegovy's I-935 to 8 March 2027 and I-973 to 15 August 2028, and Ozempic's I-961 to 28 January 2028.¹² None of them outlasts the 2031 patent, so the patent is the date to watch.

Could a US generic arrive before 2031?

Only through the courts. Two things happened in 2026 that make that path real rather than theoretical.

A US tentative approval. On 10 April 2026 Apotex said it had "received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection".⁶ Tentative approval means FDA found the application otherwise meets the standard for approval, but the product "is not an approved drug and will not be approved until FDA issues an approval".⁵ In plain terms: the science is done, the patents are not. Apotex can sell nothing in the US until a court or the calendar clears them.

A patent challenge. Novo's own half-year report says Cipla filed an ANDA for a generic Ozempic with "Paragraph IV certifications to obtain approval ... before the expiration of the patents currently listed for Ozempic® in the Orange Book", and that Novo has sued Cipla for patent infringement in federal court in New Jersey.⁷ A Paragraph IV filing is a generic maker's formal claim that a patent is invalid or would not be infringed. If the challenger wins, the date moves earlier; if Novo wins, 5 December 2031 holds. Nobody can price the outcome of that case today.

Our reading: plan on no US generic before December 2031, and treat anything earlier as upside. Major outlets round the date to 2032.¹²

Where generic semaglutide is already sold

The patents that lapsed on 20 March 2026 were foreign ones, plus the first of the two US compound patents. Here is what each market did with that date.

India: launched the next morning

"By the next morning, a dozen drugmakers were selling copies, and the cheapest now costs Rs 1,290 a month, against Rs 8,800 for Novo Nordisk's Ozempic at its Indian launch in December."¹³ CNBC reported at least five makers "undercutting the original price by up to 80%" on launch weekend.¹² Novo answered with price cuts: from 1 April, "The starting dose of both Ozempic and Wegovy fell to Rs 1,415 per weekly shot, Rs 5,660 for four weeks."¹³

The launch was not smooth for everyone. In July one of the first makers, Dr Reddy's, reported that "some batches had failed specification because of an issue with the active ingredient, and paused commercial supply in India and Canada."¹³

Canada: the first G7 approvals

Health Canada approved Dr. Reddy's generic Ozempic on 28 April 2026, "the first to be approved in the G7".⁸ Apotex followed on 1 May,⁹ and on 29 June Apotex's Sevmia became the first generic of Wegovy, approved "for chronic weight management" for patients 12 and over.¹⁰ Sandoz announced another approval on 18 September.¹¹ Dr Reddy's launched on 15 May "at a list price it described as about half of Novo's".¹³ Health Canada's own rule of thumb is that "many generic medication are 45 to 90% cheaper than the brand name versions."⁸ Novo's half-year report confirms the hit: in Canada, "the loss of exclusivity for semaglutide has led to lower realised prices".⁷

Brazil: registered, with a twist

Brazil's regulator Anvisa registered EMS's Ozivy pen on 26 May 2026, using "the same active ingredient as Ozempic, whose patent expired on March 20."¹⁴ Anvisa is careful with the word: "Ozivy is not a generic drug, since there are no generic versions of biological products according to Brazilian regulation."¹⁴ Reuters reported it reaches pharmacies only "once Brazil's medicine pricing chamber approves a price cap."¹⁵ Sandoz has since announced "the approval of Owozy™ (semaglutide) in Brazil".¹¹

China: patent gone, no generic

China's compound patent lapsed on the same day as India's, yet "the National Medical Products Administration has approved no generic or biosimilar." The reason is a data-protection rule, not a patent: "Novo says Ozempic holds data protection in China until April 2027 under the China-Switzerland free trade agreement".¹³

Why you cannot order it from Canada or India

This is the question the cheaper prices abroad raise, and the answer is no, for two separate reasons.

FDA's import rule. FDA states: "If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import."¹⁶ A Canadian or Indian generic semaglutide is exactly that: approved there, not approved here. FDA's narrow personal-use allowance is for a serious condition "for which effective treatment may not be available domestically".¹⁶ Approved semaglutide is sold in the US, by Novo itself,²⁰ so that allowance does not fit.

US patent law. Whoever "imports into the United States any patented invention during the term of the patent therefor, infringes the patent."¹⁷ The US semaglutide compound patent runs to 5 December 2031.¹ A generic made legally in India is still an unlicensed copy of a US-patented drug the moment it crosses the border.

Websites that offer "generic Ozempic shipped from India" to US addresses are selling an unapproved drug into a market where it is barred, with no US regulator checking the product. Treat any such offer as unverified, however real the Indian approval is.

What to buy instead, and what it costs today

Waiting for a generic means at least five more years. Here is what US buyers can buy now, cheapest first.

1. Compounded semaglutide: the cheapest, not FDA-approved

Compounded semaglutide is the same molecule, mixed by a licensed pharmacy. The cheapest program we verify charges $69 a month, about $830 a year. FDA's conditions for it are strict: it must be "compounded for an individual patient based on receipt of a prescription", and pharmacies may not make "essentially copies of a commercially available drug product" regularly or in large amounts. FDA also notes semaglutide is not on its drug shortage list.¹⁸ Ask any seller which pharmacy fills the prescription before you pay. Every verified semaglutide price, ranked all in:

Our is compounded semaglutide safe guide covers FDA's documented problems and how to check a pharmacy, and compounded semaglutide vs Wegovy sets the two side by side.

2. The Wegovy pill: the cheapest FDA-approved semaglutide

Novo sells the Wegovy pill for cash at "$149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg."²⁰ Through a partner program on our board, the pill starts at $208 a month all in. Novo's own 1.5 mg price is lower than the partner route. Your prescriber sets the dose.

3. Wegovy pen, self-pay

New NovoCare patients "pay $199 for each month of 0.25 mg and 0.5 mg" for two fills through 31 December 2026, "then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg and $399 per month for Wegovy® HD".²⁰ Brand Wegovy through partner programs on our board starts at $208 a month:

4. Ozempic, self-pay

Ozempic is the same molecule on a type 2 diabetes label. NovoCare charges new patients $199 a month for two fills, "then $349 per month for Ozempic® 0.25 mg, 0.5 mg or 1 mg and $499 per month for Ozempic® 2 mg."²⁰ For weight loss, Wegovy is the labelled product, and Novo prices its pen at $349 at every dose up to 2.4 mg. The full breakdown is in what Ozempic costs.

5. If you have coverage, check it first

Two programs beat every cash price on this page for the people they cover. Novo's savings card brings a covered pen or pill to as little as $25 a month, "subject to a maximum savings of $100/month", with government plans excluded.²⁰ And the Medicare GLP-1 Bridge gives eligible Part D members Wegovy, pen or tablet, "for a $50 copayment for each 30-day supply" through 31 December 2027.²¹ If either applies, $25 or $50 is your number to beat.

What a US generic might cost when it comes

Nobody has published a US generic semaglutide price, so we will not invent one. Two sourced reference points: FDA says "a single generic competitor can lead to price reductions of 30%, while five generics competing are associated with prices drops of nearly 85%."⁴ And in Canada, Health Canada puts most generics at 45 to 90% below the brand.⁸

Timeline: every date that matters

The verdict

There is no generic Ozempic or Wegovy you can legally buy in the US, and the Orange Book says there will not be one before 5 December 2031 unless a challenger wins in court. India and Canada already sell generics, but importing them is illegal for a US buyer. Today the cheapest semaglutide is compounded at $69 a month, without FDA review of the product; the cheapest FDA-approved one is the Wegovy pill at $149 a month at 1.5 mg from Novo. If Medicare's $50 Bridge or a $25 commercial card applies to you, start there.